Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Bevacizumab F(ab')2.
Recognizes Bevacizumab specifically, no cross reactivity with other humanized antibodies.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 years under sterile conditions after reconstitution.
Anti-Bevacizumab Antibodies (recommended for ADA assay) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 0.1 µg/mL, add increasing concentrations of Anti-Bevacizumab Antibodies (recommended for ADA assay) (Cat. No. BEB-Y9, 10% human serum) and then add biotinylated bevacizumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 9 ng/mL.
Demonstration of the specificity of Anti-Bevacizumab Antibodies (recommended for ADA assay) (Cat. No. BEB-Y9) to the bevacizumab.
Measured by its neutrlizing ability in a functional ELISA. Immobilized bevacizumab at 2 μg/mL (100 μL/well) can bind pre-mixed Anti-Bevacizumab Antibodies (recommended for ADA assay) (Cat. No. BEB-Y9) and Biotinylated Human VEGF 165 (Cat. No. VE5-H82Q0) with a inhibition rate of 62%.
Anti-Bevacizumab Antibodies bridging MSD for Anti-Drug Antibody (ADA) assay development. Added the mix solution (biotinylated Bevacizumab at 5 µg/mL, SULFO-Bevacizumab at 5 µg/mL and increasing concentrations of Anti-Bevacizumab Antibodies (Cat. No. BEB-Y9, 100% human serum). Detection was performed using MSD Assay with a sensitivity of 0.97 ng/mL.
Anti-Bevacizumab Antibodies (recommended for ADA assay) (mouse IgG1, Cat. No. BEB-Y9) captured on CM5 chip via anti-mouse antibodies surface, can bind human bevacizumab with an affinity constant of 1.92 nM.
A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.